Document:

rpay-ex1026_121.htm

 

 

Exhibit 10.26

 

Repay Holdings Corporation (the “Company”)

 

Summary of Non-Employee Director Compensation (as of April 1, 2022)

 

 

 

 

		
	
Annual Cash Retainer
	
$40,000

	
[Paid quarterly in arrears on October 1, January 1, April 1 and July 1 of each year]
	
 

	
Annual Equity Award
	
 

 

	
Non-Executive Chairman

Other Non-Employee Directors

 

Awarded to new directors upon appointment and to incumbent directors at each shareholders’ meeting, in the form of restricted stock units, calculated based on the closing price on the date of grant (or the most recent trading day if such date is not a trading day) and rounded down to the nearest whole unit. Restricted stock units vest on the earlier of (x) the first anniversary of the date of grant and (y) the next regularly scheduled annual shareholder meeting occurring in the year following the year of the date of grant. Vesting also accelerates upon a change of control or termination from service as a result of the director’s death or disability. Vested restricted stock units are settled on the earlier of (x) the date the director undergoes a “separation from service” as defined in Section 409A of the Internal Revenue Code and (y) a change of control.
	
$250,000

$170,000

	
 

Non-Executive Chairman Fee

[Paid quarterly in arrears on October 1, January 1, April 1 and

July 1 of each year]

 

 

 

 

 

 

Committee Chair Fees

 
	
$20,000

 

 

 

		
	
[Paid quarterly in arrears on October 1, January 1, April 1 and

July 1 of each year]
	
 

	
Audit Committee Chairperson
	
$20,000

	
Compensation Committee Chairperson
	
$15,000

	
Committee Chairperson (other than Audit and Compensation)
	
$10,000

	
Committee Fees

 
	
 

	
[Paid quarterly in arrears on October 1, January 1, April 1 and

July 1 of each year]
	
 

	
Audit Committee Member
	
$7,500

	
Committee Member (other than Audit)
	
$5,000

 

 

 

***

 

In addition, the Company will reimburse directors for their reasonable out-of- pocket expenses incurred in connection with attending board and committee meetings.rpay-ex1030_66.htm

Exhibit 10.30

REPAY HOLDINGS CORPORATION
RESTRICTED STOCK AWARD AGREEMENT

THIS RESTRICTED STOCK AWARD AGREEMENT (the “Award Document”) is hereby granted as of      [DATE]    , 2022 (the “Grant Date”) by Repay Holdings Corporation, a Delaware corporation (the “Company”), to    [NAME]        (the “Grantee”) pursuant to the Repay Holdings Corporation Omnibus Incentive Plan (as amended, the “Plan”) and subject to the terms and conditions set forth therein and as set out in this Award Document.  Capitalized terms used herein shall, unless otherwise required by the context, have the meaning ascribed to such terms in the Plan.  

By action of the Committee, and subject to the terms of the Plan, the Grantee is hereby granted an Award of      [NUMBER]     Shares (the “Shares”), subject in all regards to the terms of the Plan and to the restrictions set forth in this Award Document.

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained in this Award Document, the Company and the Grantee agree as follows:

1.Grant.  The Company hereby grants to the Grantee the Shares, on the terms and conditions set forth in this Award Document and as otherwise set forth in the Plan.  

2.Vesting.   

(a)Vesting.  The Shares shall be 100% vested on the Grant Date.  

(b)No Forfeiture.  The Shares are not subject to forfeiture, including upon the Grantee’s termination of employment with the Company or its Affiliates for any reason, except as set forth in Section 3 below. 

(c)Rights as a Stockholder.  The Grantee, immediately following grant of the Shares, shall have all of the rights of a stockholder of the Company with respect to the Shares that are issued to Grantee, subject to Section 5 below.  

(d)Withholding for Taxes.  Grantee will be taxed on the fair market value of the Shares as of the Grant Date. Withholding of any portion of the Shares in connection with the Company’s withholding obligations arising on account of the grant of vested Shares shall be deemed to be a taxable repurchase of such withheld Shares for federal income tax purposes at the time of grant.  

3.Clawback.  The Shares and this Restricted Stock Award are subject to the Compensation Recovery provisions of the Plan.  In the event the Company (or any successor thereof) is required to provide an accounting restatement for any of the prior three fiscal years of the Company for which audited financial statements have been completed as a result of material noncompliance with financial reporting requirements under federal securities laws (a “Restatement”), the amount of any Excess Compensation 

 

 

realized by any Executive Officer shall be subject to recovery by the Company (or any successor thereof).

4.Compliance with Legal Requirements. The granting and delivery of the Shares and any other obligations of the Company under this Award Document, shall be subject to all applicable federal, state, local and foreign laws, rules and regulations and to such approvals by any regulatory or governmental agency as may be required. 

5.Transferability.  During the period commencing on the Grant Date and ending on the first anniversary of the Grant Date, the Shares may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Grantee and any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or any Affiliate (or any successor thereof).  If, prior to the first anniversary of the Grant Date, there is a Change of Control or the Grantee’s employment with the Company and its Affiliates (or any successor thereof) is terminated on account of Grantee’s death or Incapacity, then the foregoing transfer restrictions shall terminate immediately upon such event.  In addition, the foregoing transfer restrictions shall not apply to transfers of all or any of the Shares as a bona fide gift or for bona fide estate planning purposes; provided, however, in the case of any such transfer, each transferee shall agree in writing to be bound by the terms and conditions of this Award Document.  

6.Waiver. Any right of the Company (or any successor thereof) contained in this Award Document may be waived in writing by the Committee.  No waiver of any right hereunder by any party shall operate as a waiver of any other right, or as a waiver of the same right with respect to any subsequent occasion for its exercise, or as a waiver of any right to damages.  

7.Severability.  The invalidity or unenforceability of any provision of this Award Document shall not affect the validity or enforceability of any other provision of this Award Document, and each other provision of this Award Document shall be severable and enforceable to the extent permitted by law. 

8.Employment.  Nothing in the Plan or in this Award Document shall be construed to imply or to constitute evidence of any agreement, express or implied, on the part of the Company or any Affiliate (or any successor thereof) to retain the Grantee in the employ of the Company or an Affiliate (or any successor thereof) and/or, if applicable, as a member of the Company’s Board of Directors or in any other capacity.

9.Binding Effect.  The terms of this Award Document shall be binding upon and shall inure to the benefit of the Company, its successors and assigns, the Grantee and the transferees, beneficiaries, executors, administrators and heirs of the Grantee.   

10.Entire Agreement.  This Award Document and the Plan contain the entire agreement and understanding of the parties hereto with respect to the subject matter contained herein and supersedes all prior communications, representations and negotiations in respect thereto.  In the event of a conflict between the Plan and this 

- 2 -

 

Award Document, the terms of the Plan shall control.  No change, modification or waiver of any provision of this Award Document shall be valid unless the same be in writing and signed by the parties hereto, except for any changes permitted without consent of the Grantee under the Plan.

11.Governing Law. This Award Document shall, except to the extent preempted by federal law, be construed and interpreted in accordance with the laws of the State of Delaware without regard to principles of conflicts of law thereof, or principles of conflicts of laws of any other jurisdiction which could cause the application of the laws of any jurisdiction other than the State of Delaware. 

	
12
	
Section 409A.  The grant of Shares under this Agreement will not be considered deferred compensation within the meaning of Section 409A of the Code.  

	
13.
	
Counterparts.  This Award Document may be executed in a number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

 

IN WITNESS WHEREOF, this Award Document has been executed on this __ day of ___________________, 2022.  

REPAY HOLDINGS CORPORATION

 

 

 

By: ________________________________

Its [TITLE]

 

 

ACKNOWLEDGED

 

 

 

By: ________________________________

       Grantee 

 

- 3 -Exhibit 10.2

 

 

 

TriplePoint
Venture Growth BDC Corp.

 

Second Supplement to Master Note Purchase
Agreement

 

Dated
as of February 28, 2022

 

Re:       $125,000,000 5.00% Series
2022A Senior Notes

Due
February 28, 2027

 

 

 

 

 

 

 

 

     

     

    

 

TriplePoint Venture Growth BDC
Corp.

 

Dated as of

February 28, 2022

 

To the Additional Purchaser(s) named in

Schedule A hereto

 

Ladies and Gentlemen:

 

This Second Supplement to
Master Note Purchase Agreement (the or this “Supplement”) is between TriplePoint Venture Growth BDC Corp., a Maryland
corporation (the “Company”), and the institutional investors named on Schedule A attached hereto (the “Additional
Purchasers”).

 

Reference is hereby made to
that certain Master Note Purchase Agreement dated March 19, 2020 (the “Note Purchase Agreement”) among the Company
and the Purchasers listed on the Purchaser Schedule thereto. All capitalized terms not otherwise defined herein shall have the same meaning
as specified in the Note Purchase Agreement. Reference is further made to Section 4.14 of the Note Purchase Agreement which requires
that, prior to the delivery of any Additional Notes, the Company and each Additional Purchaser shall execute and deliver a Supplement.

 

The Company hereby agrees
with the Additional Purchaser(s) as follows:

 

 1. The Company has authorized the issue
and sale of $125,000,000 aggregate principal amount of its 5.00% Series 2022A Senior Notes due February 28, 2027 (as
amended, restated or otherwise modified from time to time pursuant to Section 17 of the Note Purchase Agreement and including any
such notes issued in substitution therefor pursuant to Section 13 of the Note Purchase Agreement the “Series 2022A Notes”).
The Series 2022A Notes, together with the Series 2020A Notes issued pursuant to the Note Purchase Agreement, the Series 2021A Notes
issued pursuant to the First Supplement to Master Note Purchase Agreement dated as of March 1, 2021 and each series of Additional
Notes which may from time to time hereafter be issued pursuant to the provisions of Section 2.2 of the Note Purchase Agreement, are
collectively referred to as the “Notes” (such term shall also include any such notes issued in substitution therefor
pursuant to Section 13 of the Note Purchase Agreement). The Series 2022A Notes shall be substantially in the form set out in Exhibit 1
hereto with such changes therefrom, if any, as may be approved by the Additional Purchaser(s) and the Company.

 

 2. Subject to the terms and conditions
hereof and as set forth in the Note Purchase Agreement and on the basis of the representations and warranties hereinafter set forth, the
Company agrees to issue and sell to each Additional Purchaser, and each Additional Purchaser agrees to purchase from the Company, Series
2022A Notes in the principal amount set forth opposite such Additional Purchaser’s name on Schedule A hereto at a price
of 100% of the principal amount thereof on the closing date hereinafter mentioned.

 

     

     

    

 

 3. The sale and purchase of the Series
2022A Notes to be purchased by each Additional Purchaser shall occur at the offices of Chapman and Cutler LLP, 320 South Canal Street,
Chicago, Illinois 60606, at 8:00 a.m. Chicago time on February 28, 2022 or on such other Business Day thereafter on or prior to March
2, 2022 as may be agreed upon by the Company and the Additional Purchasers (the “Series 2022A Closing”). At the Series
2022A Closing, the Company will deliver to each Additional Purchaser the Series 2022A Notes to be purchased by such Additional Purchaser
in the form of a single Series 2022A Note (or such greater number of Series 2022A Notes in denominations of at least $100,000 as such
Additional Purchaser may request) dated the date of the Series 2022A Closing and registered in such Additional Purchaser’s name
(or in the name of such Additional Purchaser’s nominee), against delivery by such Additional Purchaser to the Company or its order
of immediately available funds in the amount of the purchase price therefor by wire transfer of immediately available funds for the account
of the Company pursuant to the applicable funding instructions delivered in accordance with Section 4.10 of the Note Purchase Agreement.
If, at the Series 2022A Closing, the Company shall fail to tender such Series 2022A Notes to any Additional Purchaser as provided above
in this Section 3, or any of the conditions specified in Section 4 shall not have been fulfilled to any Additional Purchaser’s
satisfaction, such Additional Purchaser shall, at such Additional Purchaser’s election, be relieved of all further obligations under
this Agreement, without thereby waiving any rights such Additional Purchaser may have by reason of such failure by the Company to tender
such Series 2022A Notes or any of the conditions specified in Section 4 not having been fulfilled to such Additional Purchaser’s
satisfaction.

 

 4. The obligation of each Additional Purchaser
to purchase and pay for the Series 2022A Notes to be sold to such Additional Purchaser at the Series 2022A Closing is subject to the fulfillment
to such Additional Purchaser’s satisfaction, prior to the Series 2022A Closing, of the conditions set forth in Section 4 of
the Note Purchase Agreement with respect to the Series 2022A Notes to be purchased at the Series 2022A Closing as if each reference to
the “Notes,” “Closing” and “Purchaser” set forth therein was modified to refer the “Series 2022A
Notes,” the “Series 2022A Closing” and the “Additional Purchaser” (each as defined in this Supplement)
and to the following additional conditions:

 

 (a) Except as supplemented, amended
or superseded by the representations and warranties set forth in Exhibit A hereto, each of the representations and warranties of
the Company set forth in Section 5 of the Note Purchase Agreement shall be true and correct as of the date of the Series 2022A Closing
(except for representations and warranties which apply to a specific earlier date (other than the date of an earlier Closing) which shall
be true and correct as of such earlier date or as of the date specified in Exhibit A to the extent such provision is superseded
in Exhibit A) and the Company shall have delivered to each Additional Purchaser an Officer’s Certificate, dated the
date of the Series 2022A Closing certifying that such condition has been fulfilled.

 

 (b) Contemporaneously with the
Series 2022A Closing, the Company shall sell to each Additional Purchaser, and each Additional Purchaser shall purchase, the Series 2022A
Notes to be purchased by such Additional Purchaser at the Series 2022A Closing as specified in Schedule A.

 

    -2- 

     

    

 

 5. The terms of Section 8 of the Note
Purchase Agreement shall apply to the Series 2022A Notes except that the proviso in the first sentence of Section 8.2 of the
Note Purchase Agreement shall be amended and restated in its entirety to read as follows:

 

“provided,
that at any time on or after March 19, 2024 the Company may, at its option, upon notice
as provided below, prepay all or any part of the Series 2020A Notes at 100% of the principal amount so prepaid, together with accrued
interest to the prepayment date; provided further, that at any time on or after March 1, 2025 the Company may, at its option, upon
notice as provided below, prepay all or any part of the Series 2021A Notes at 100% of the principal amount so prepaid, together with
accrued interest to the prepayment date; provided further, that at any time on or after February 28, 2026 the Company may, at its
option, upon notice as provided below, prepay all or any part of the Series 2022A Notes at 100% of the principal amount so prepaid,
together with accrued interest to the prepayment date.” 

 

For the avoidance of doubt,
the definition of “Make-Whole Amount” set forth in Section 8.6 of the Note Purchase Agreement shall be applicable
to any Series 2022A Note.

 

 6. Each Additional Purchaser represents
and warrants that the representations and warranties set forth in Section 6 of the Note Purchase Agreement are true and correct on the
date hereof with respect to the purchase of the Series 2022A Notes by such Additional Purchaser as if (x) each reference to the “Notes,”
“Closing” and “Purchaser” set forth therein was modified to refer the “Series 2022A Notes,” the “Series
2022A Closing” and the “Additional Purchaser” and each reference to “this Agreement” therein was modified
to refer to the Note Purchase Agreement as supplemented by this Supplement, (y) the reference to “(ii) the Annual Report on Form
10-K for the Company for the fiscal year ended December 31, 2018, (iii) the Quarterly Report on Form 10-Q for the Company for the quarter
ended September 30, 2019” set forth in Section 6.3 was modified to refer to “(ii) the Annual Report on Form 10-K for the Company
for the fiscal year ended December 31, 2020, (iii) the Quarterly Report on Form 10-Q for the Company for the quarter ended September 30,
2021” and (z) the following clause were added before the period at the end of Section 6.5 “, except to the extent arising
from fraud, gross negligence or willful misconduct of Goldman Sachs, any of its Affiliates or any other of the foregoing Persons.”

 

 7. The Company and each Additional Purchaser
agree to be bound by and comply with the terms and provisions of the Note Purchase Agreement as fully and completely as if such Additional
Purchaser were an original signatory to the Note Purchase Agreement.

 

The execution hereof shall
constitute a contract between the Company and the Additional Purchaser(s) for the uses and purposes hereinabove set forth, and this agreement
may be executed in any number of counterparts, each executed counterpart constituting an original but all together only one agreement.
The parties agree to electronic contracting and signatures with respect to this Supplement.  Delivery of an electronic signature
to, or a signed copy of, this Supplement by facsimile, email or other electronic transmission shall be fully binding on the parties
to the same extent as the delivery of the signed originals and shall be admissible into evidence for all purposes.

 

[Remainder of Page Intentionally
Left Blank]

 

    -3- 

     

    

 

	 	TriplePoint
    Venture Growth BDC Corp.
	 	 	 	 
	 	By	/s/
    Christopher M. Mathieu
	 	 	Name: 	Christopher M. Mathieu
	 	 	Title:	Chief Financial Officer

 

The
foregoing is hereby

agreed
to as of the

date
thereof.

 

	 	The Guardian
    Life Insurance Company of America
	 	 	 	 
	 	By:	/s/
    Barry Scheinholtz
	 	 	Name: 	Barry Sheinholtz
	 	 	Title:	Managing Director

 

	 	Fidelity &
    Guaranty Life Insurance Company
	 	 
	 	By:	Aspida Life Re Ltd., its investment
    manager
	 	By:	Ares Insurance Solutions LLC, its sub-advisor
	 	By:	Ares Alternative Credit Management LLC, its sub-advisor

  

	 	By:	/s/
    Kevin Alexander
	 	 	Name:	Kevin Alexander
	 	 	Title:	Partner

 

     

     

    

 

	 	Southern
    Atlantic Re Inc.
	 	 	 	 
	 	By:	Aspida
    Life Re Ltd., its investment manager
	 	By:	Ares
    Insurance Solutions LLC, its sub-advisor
	 	By:	Ares
    Alternative Credit Management LLC, its sub-advisor
	 	 	 	 
	 	By:	/s/
    Kevin Alexander
	 	 	Name: 	Kevin Alexander
	 	 	Title:	Partner
	 	 	 	 
	 	Capital
    Life Insurance Company
	 	 	 	 
	 	By:	Aspida
    Life Re Ltd., its investment manager
	 	By:	Ares
    Insurance Solutions LLC, its sub-advisor
	 	By:	Ares
    Alternative Credit Management LLC, its sub-advisor
	 	 	 	 
	 	By:	/s/
    Kevin Alexander
	 	 	Name:	Kevin Alexander
	 	 	Title:	Partner
	 	 	 	 
	 	American
    General Life insurance Company
	 	American
    Home Assurance Company
	 	 	 	 
	 	By:	AIG
    Asset Management (U.S.), as Investment Adviser
	 	 	 	 
	 	By:	/s/
    Craig Moody
	 	 	Name:	Craig Moody
	 	 	Title:	Senior Vice President

 

     

     

    

 

	 	Sun
    Life Assurance Company of Canada, acting through
    its Bermuda Branch
	 	 	 	 
	 	By:	/s/
    Alec Svoboda
	 	 	Name: 	Alec Svoboda
	 	 	Title:	Managing Director, Private
    Fixed Income
	 	 	 	 
	 	By:	/s/
    Russel Goldenberg
	 	 	Name:	Russel Goldenberg
	 	 	Title:	Senior Director, Private Fixed
    Income
	 	 	 	 
	 	SunLife
    Assurance Company of Canada,
	 	acting through
    its U.S. Branch
	 	 	 	 
	 	By:	/s/
    David Belanger
	 	 	Name:	David Belanger
	 	 	Title:	Managing Director
	 	 	 	 
	 	By:	/s/Art
    Baril
	 	 	Name:	Art Baril
	 	 	Title:	Senior Director
	 	 	 	 
	 	NDG
    I, LLC
	 	 
	 	By:  	Sun Life Capital
    Management (U.S.) LLC, its Investment Advisor
	 	 	 	 
	 	By:	/s/
    David Belanger
	 	 	Name:	David Belanger
	 	 	Title:	Managing Director
	 	 	 	 
	 	By:	/s/
    Art Baril
	 		Name:	Art Baril
	 		Title:	Senior Director

 

     

     

    

 

	 	CSAA
    Insurance Exchange
	 	 
	 	By:	Sun
    Life Capital Management (U.S.) LLC, its Investment Advisor
	 	 	 	 
	 	By:	/s/
    David Belanger
	 	 	Name: 	David Belanger
	 	 	Title:	Managing Director
	 	 	 	 
	 	By:	/s/
    Art Baril
	 	 	Name:	Art Baril
	 	 	Title:	Senior Director
	 	 	 	 
	 	Somerset
    Reinsurance Ltd., as Reinsurer and Authorized Party,
    on behalf of Catholic United Financial
	 	 
	 	By:	Sun Life Capital
    Management (U.S.) LLC, its Investment Adviser
	 	 	 	 
	 	By:	/s/
    David Belanger
	 	 	Name:	David Belanger
	 	 	Title:	Managing Director
	 	 	 	 
	 	By:	/s/
    Art Baril
	 	 	Name:	Art Baril
	 	 	Title:	Senior Director
	 	 	 	 
	 	Axis
    Specialty Insurance Company
	 	 
	 	By:	Sun Life Capital
    Management (U.S.) LLC, its Investment Adviser
	 	 	 	 
	 	By:	/s/
    David Belanger
	 	 	Name:	David Belanger
	 	 	Title:	Managing Director
	 	 	 	 
	 	By:	/s/
    Art Baril
	 	 	Name:	Art Baril
	 	 	Title:	Senior Director

 

     

     

    

 

	 	Arch Reinsurance Company
	 	 
	 	By:	/s/ Shaya Altschuller
	 	 	Name: 	Shaya Altschuller
	 	 	Title:	Corporate Controller
	 	 
	 	Arch Insurance Company
	 	 
	 	By:	/s/ Elizabeth DeChiara
	 	 	Name:	Elizabeth DeChiara
	 	 	Title:	Vice President
	 	 
	 	Chubb Life Insurance Company Ltd.
	 	 
	 	By:	/s/ Chen Lin
	 	 	Name:	Chen Lin
	 	 	Title:	Portfolio Manager, Chubb Life
	 	 
	 	Teachers Insurance and Annuity Association of America, a New York domiciled life insurance company

 

	 	By:	Nuveen Alternatives Advisors LLC, a Delaware limited liability company, its investment manager

 

	 	By:	/s/ Ho Young Lee
	 	 	Name: 	Ho Young Lee
	 	 	Title:	Managing Director

 

     

     

    

 

	 	The Toa Reinsurance Company of America Converge Asset Management LLC Western Asset Basel III Efficient Portfolio Series Interests of the SALI SVW Multi-Series Fund, L.P.
	 	 	 	 
	 	By: 	Western Asset Management Company, LLC, as investment manager
	 	 	 
	 	By:  	/s/ Adam Wright
	 		Name: 	Adam Wright
	 		Title:	Manager, U.S. Legal Affairs
	 	 	 	 
	 	The Ohio
National Life Insurance Company
	 	 	 	 
	 	By:  	/s/ Brenda Kalb
	 		Name:	Brenda Kalb
	 	 	Title: 	Vice President
	 	 	 	 
	 	Farmer Bureau Life Insurance Company 
	 	 	 	 
	 	By:  	/s/ Michael Warmuth
	 	 	Name:  	Michael Warmuth
	 	 	Title: 	Securities Vice President
	 	 	 	 
	 	Great American Insurance Company
	 	 	 	 
	 	By: 	/s/ Stephen C. Beraha
	 		Name:	Stephen C. Beraha
	 		Title:	Assistant Vice President
	 	 	 	 
	 	EquiTrust Life Insurance Company
	 	 	 	 
	 	By: 	/s/ Kenyatta K. Matheny
	 		Name:	Kenyatta K. Matheny
	 		Title:	Chief Investment Officer

 

     

     

    

 

Supplemental Representations

 

The Company represents and
warrants to each Additional Purchaser that except as hereinafter set forth in this Exhibit A, each of the representations and warranties
set forth in Section 5 of the Note Purchase Agreement (other than representations and warranties that apply solely to a specific
earlier date (other than the date of an earlier Closing) which shall be true and correct as of such earlier date and other than the Section
references hereinafter set forth) is true and correct in all material respects as of the date hereof with respect to the Series 2022A
Notes with the same force and effect as if each reference to “Notes,” “Closing” and “Purchaser” set
forth therein was modified to refer to “Series 2022A Notes,” “Series 2022A Closing” and “Additional Purchaser”
and each reference to “this Agreement” therein was modified to refer to the Note Purchase Agreement as supplemented by the
Supplement. The Section references hereinafter set forth correspond to the similar Sections of the Note Purchase Agreement which
are supplemented hereby:

 

 Section 5.3. Disclosure. (a)
The Company, through its agent, Goldman Sachs, has delivered to each Additional Purchaser a copy of an Investor Presentation dated January
2022 (the “Presentation”), relating to the transactions contemplated hereby in connection with the Series 2022A Notes.
The Presentation, when read together with the information incorporated therein by reference to the Company’s Exchange Act filings,
fairly describes, in all material respects, the general nature of the business and principal properties of the Company and its Subsidiaries.
This Agreement, the Presentation (including the information incorporated therein by reference to the Company’s Exchange Act filings),
the financial statements listed in Schedule 5.5 and the documents, certificates or other writings delivered to the Additional Purchasers
by or on behalf of the Company (other than financial projections, pro forma financial information and other forward-looking information
referenced in Section 5.3(b), information relating to third parties and general economic information) prior to February 16, 2022 in connection
with the transactions contemplated hereby and identified in Schedule 5.3 (this Agreement, the Presentation (including the information
incorporated therein by reference to the Company’s Exchange Act filings) and such documents, certificates or other writings and
such financial statements delivered to each Additional Purchaser being referred to, collectively, as the “Disclosure Documents”),
taken as a whole, do not contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements
therein not misleading in light of the circumstances under which they were made. Except as disclosed in the Disclosure Documents, since
September 30, 2021, there has been no change in the financial condition, operations, business or properties of the Company or any Subsidiary
except changes that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. There is no
fact known to the Company that would reasonably be expected to have a Material Adverse Effect that has not been set forth herein or in
the Disclosure Documents.

 

 (b)  All financial projections, pro forma
financial information and other forward-looking information which has been delivered to each Additional Purchaser by or on behalf of the
Company in connection with the transactions contemplated by this Agreement are based upon good faith assumptions and, in the case of financial
projections and pro forma financial information, good faith estimates, in each case, believed to be reasonable at the time made, it being
recognized that (i) such financial information as it relates to future events is subject to significant uncertainty and contingencies
(many of which are beyond the control of the Company) and are therefore not to be viewed as fact, and (ii) actual results during the period
or periods covered by such financial information may materially differ from the results set forth therein.

 

EXHIBIT A

(to Supplement)

 

     

     

    

 

 Section 5.4. Organization and Ownership
of Shares of Subsidiaries. (a) Schedule 5.4 contains (except as noted therein) complete and correct lists as of the date of the
Series 2022A Closing of (i) the Company’s Subsidiaries, showing, as to each Subsidiary, the name thereof, the jurisdiction
of its organization, the percentage of shares of each class of its capital stock or similar equity interests outstanding owned by the
Company and each other Subsidiary and whether such Subsidiary is a Subsidiary Guarantor, and (ii) the Company’s directors and
executive officers.

 

 Section 5.5. Financial Statements;
Material Liabilities. The Company has delivered to each Additional Purchaser copies of the financial statements of the Company and
its Subsidiaries listed on Schedule 5.5. All of such financial statements (including in each case the related schedules and notes,
but excluding all financial projections, pro forma financial information and other forward-looking information) fairly present in all
material respects the consolidated financial position of the Company and its Subsidiaries as of the respective dates specified in such
Schedule 5.5 and the consolidated results of their operations and cash flows (as applicable) for the respective periods so specified
and have been prepared in accordance with GAAP consistently applied throughout the periods involved except as set forth in the notes thereto
(subject, in the case of any interim financial statements, to normal year-end adjustments and lack of footnotes).

 

 Section 5.13. Private Offering
by the Company. Neither the Company nor anyone acting on its behalf has offered the Series 2022A Notes or any substantially similar
debt Securities for sale to, or solicited any offer to buy the Series 2022A Notes or any substantially similar debt Securities from,
or otherwise approached or negotiated in respect thereof with, any Person other than the Additional Purchasers and not more than 75 other
Institutional Investors, each of which has been offered the Series 2022A Notes at a private sale for investment. Neither the Company
nor anyone acting on its behalf has taken, or will take, any action that would subject the issuance or sale of the Series 2022A Notes
to the registration requirements of section 5 of the Securities Act or to the registration requirements of any Securities or blue
sky laws of any applicable jurisdiction.

 

 Section 5.14. Use of Proceeds;
Margin Regulations. The Company will apply the proceeds of the sale of the Series 2022A Notes hereunder as described in Schedule 5.14.
No part of the proceeds from the sale of the Series 2022A Notes hereunder will be used, directly or indirectly, for the purpose of buying
or carrying any margin stock within the meaning of Regulation U of the Board of Governors of the Federal Reserve System (12 CFR 221),
or for the purpose of buying or carrying or trading in any Securities under such circumstances as to involve the Company in a violation
of Regulation X of said Board (12 CFR 224) or to involve any broker or dealer in a violation of Regulation T of said Board (12
CFR 220). Margin stock does not constitute more than 25.0% of the value of the consolidated assets of the Company and its subsidiaries
and the Company does not have any present intention that margin stock will constitute more than 25.0% of the value of such assets. As
used in this Section, the terms “margin stock” and “purpose of buying or carrying” shall have the meanings assigned
to them in said Regulation U.

 

 Section 5.15. Existing Indebtedness;
Future Liens. (a) Except as described therein, Schedule 5.15 sets forth a complete and correct list of all outstanding Indebtedness
of the Company and its Subsidiaries as of the last day of the month immediately preceding the date
of the Series 2022A Closing, since which date there has been no Material change in the amounts, interest rates, sinking funds,
installment payments or maturities of the Indebtedness of the Company or its Subsidiaries. As of
the last day of the month immediately preceding the date of the Series 2022A Closing, neither the Company nor any Subsidiary is
in default and no waiver of default is currently in effect, in the payment of any principal or interest on any Indebtedness of the Company
or such Subsidiary and, to the knowledge of the Company, no event or condition exists with respect to any Indebtedness of the Company
or any Subsidiary that would permit (or that with notice or the lapse of time, or both, would permit) one or more Persons to cause such
Indebtedness to become due and payable before its stated maturity or before its regularly scheduled dates of payment.

 

Schedules 5.3, 5.4, 5.5, 5.14,
5.15, 10.1 and 10.5 of the Note Purchase Agreement are hereby supplemented by the attached Schedules 5.3, 5.4, 5.5, 5.14, 5.15, 10.1 and
10.5.

 

    A-2

     

    

 

[Form of Series 2022A Note]

 

TriplePoint
Venture Growth BDC Corp.

 

5.00% Series 2022A Senior Note due February 28, 2027

 

	No. [_________]	February 28, 2022
	$[____________]	PPN 89677Y A#7

 

For
Value Received, the undersigned, TriplePoint Venture Growth BDC Corp. (herein
called the “Company”), a corporation organized and existing under the laws of the State of Maryland, hereby promises
to pay to [____________], or registered assigns, the principal sum of [_____________________] Dollars
(or so much thereof as shall not have been prepaid) on February 28, 2027 (the “Maturity Date”), with interest (computed
on the basis of a 360-day year of twelve 30-day months) (a) on the unpaid balance hereof at the rate of 5.00% per annum, as may be
adjusted in accordance with Section 1.2 of the Note Purchase Agreement (as hereinafter defined), from the date hereof, payable semiannually,
on the 28th day of February and August in each year, commencing with August 28, 2022, and on the Maturity Date, until the principal hereof
shall have become due and payable, and (b) to the extent permitted by law, (x) on any overdue payment of interest and (y) during
the continuance of an Event of Default, on such unpaid balance and on any overdue payment of any Make-Whole Amount (if any), at a rate
per annum from time to time equal to the Default Rate, payable semiannually as aforesaid (or, at the option of the registered holder hereof,
on demand).

 

Payments of principal of,
interest on and any Make-Whole Amount with respect to this Note are to be made in lawful money of the United States of America at the
Company in New York, New York or at such other place as the Company shall have designated by written notice to the holder of
this Note as provided in the Note Purchase Agreement referred to below.

 

This Note is one of a series
of Senior Notes (the “Notes”) issued pursuant to a Supplement dated as of February 28, 2022 to the Note Purchase Agreement,
dated March 19, 2020 (as from time to time amended, supplemented or modified, the “Note Purchase Agreement”),
among the Company, the Purchasers named therein and Additional Purchasers of Notes from time to time issued pursuant to any Supplement
to the Note Purchase Agreement. This Note and the holder hereof are entitled with the holders of all other Notes of all series from time
to time outstanding under the Note Purchase Agreement to all the benefits provided for thereby or referred to therein. Each holder of
this Note will be deemed, by its acceptance hereof, to have (i) agreed to the confidentiality provisions set forth in Section 20
of the Note Purchase Agreement and (ii) made the representations set forth in Section 6 of the Note Purchase Agreement. Unless
otherwise indicated, capitalized terms used in this Note shall have the respective meanings ascribed to such terms in the Note Purchase
Agreement.

 

     

     

    

 

This Note is a registered
Note with the Company and, as provided in (and subject to the terms and conditions of) the Note Purchase Agreement, upon surrender of
this Note for registration of transfer accompanied by a written instrument of transfer duly executed, by the registered holder hereof
or such holder’s attorney duly authorized in writing, a new Note of the same series for a like principal amount will be issued to,
and registered in the name of, the transferee. Prior to due presentment for registration of transfer, the Company may treat the Person
in whose name this Note is registered as the owner hereof for the purpose of receiving payment and for all other purposes, and the Company
will not be affected by any notice to the contrary.

 

This Note is not subject to
regularly scheduled prepayments of principal. This Note is subject to optional prepayment, in whole or from time to time in part, on the
terms specified in the Note Purchase Agreement.

 

If an Event of Default occurs
and is continuing, the principal of this Note may be declared or otherwise become due and payable in the manner, at the price (including
any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreement.

 

This Note shall be construed
and enforced in accordance with, and the rights of the Company and the holder of this Note shall be governed by, the law of the State
of New York excluding choice-of-law principles of the law of such State that would permit the application of the laws of a jurisdiction
other than such State.

 

	 	TriplePoint Venture Growth BDC Corp.
	 	 	 
	 	By:	 
	 	 	Name: 	          
	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]